Immunoglobulin Market Latest Treatment, Upcoming Advancement, Global Size Analysis, Share, Growth Insights to 2026 by coherentmarketinsights.com

Global Immunoglobulin Market – Insights

An immunoglobulin (IG), also known as an antibody, is a protein produced mainly by plasma cells. The immune system uses IGs to neutralize pathogens such as pathogenic bacteria and viruses. The immune response of IG is highly complex and very specific. There are different types of IGs that differ in their biological features, structure, target specificity, and distribution such as IgG, IgA, and IgM. These IGs can be administered intravenously and subcutaneously for the treatment of various immunological and neurological diseases such as multiple sclerosis, Primary Humoral Immunodeficiency (PIDD), Immune Thrombocytopenia Purpura (ITP), and autoimmune haemolytic anemia. IG also finds application in the field of hematology, neurology, immunology, dermatology, ophthalmology, nephrology and rheumatology. Assessment of the IG isotype can offer valuable perspective regarding complex humoral immune response.

Get FREE Sample PDF Including COVID-19 Impact Analysis: https://www.coherentmarketinsights.com/insight/request-sample/1712

Global Immunoglobulin Market: Drivers

Increasing adoption of immunoglobulin in the treatment of various diseases is expected to boost growth of the global immunoglobulin market. Moreover, increasing approvals of intravenous products is also expected to boost the market growth. For instance, in May 2018, ADMA Biologics, Inc. announced that the company received U.S. patent till January 2035 for the usage of polyclonal immunoglobulin preparation for the treatment of respiratory infection. Moreover, in May 2018, Kedrioin Biopharma and Kamada Ltd. together launched two human-derived protein therapeutics. The companies launched KEDRAB [Rabies Immune Globulin (Human)] in the U.S. as it received the U.S. Food and Drug Administration approval for passive, transient post-exposure prophylaxis of rabies infection, when given immediately after contact with a rabid or possibly rabid animal and concurrent with the rabies vaccine.

Furthermore, increasing prevalence of Primary Immunodeficiency Disease (PID) is expected to boost growth of the global immunoglobulin market. For instance, according to the Centers for Disease Control and Prevention (CDC), in 2012, the incidence rate of hypogammaglobulinemia worldwide was around 2 per 100,000 populations. Increasing geriatric population prone to develop diseases due to low antibody immune response of body is also expected to contribute to growth of the market.

LIMITED TIME OFFER – Hurry Up!

Get Discount For Buyers UPTO 25% OFF On Any Research Report
Apply Promo Code “CHRISTMAS2020” And Get Instant Discount Of USD 1000
Buy Now This Premium Report to Grow your Business @ https://www.coherentmarketinsights.com/insight/buy-now/1712

Global Immunoglobulin Market: Restraints  

High cost of treatment, long-term side-effects, stringent regulatory framework, and emergence of alternative therapies such recombinant products are some of the factors hindering growth of the globqal immunoglobulin market.

Global Immunoglobulin Market – Regional Analysis

North America held dominant position in the global immunoglobulin market, followed by Europe in 2016, owing to increasing number approvals for immunoglobulin. For instance, in 2016, Shire plc. announced the launch of CUVITRU [Immune Globulin Subcutaneous (Human), 20% Solution] the first and only Subcutaneous 20% treatment option without proline available in the U.S. for the treatment of adult and pediatric patients (two years of age and older) with primary immunodeficiency (PI).

Global Immunoglobulin Market – Competitive Analysis

Key players operating in the global immunoglobulin market include China Biologics Products, Inc., BDI Pharma Inc., Bayer Healthcare, Baxter international Inc., CSL Ltd., Grifols S.A, Octapharma AG, Kedrion Biopharma Inc., LFB group, Biotest AG, Hualan Biological Engineering Inc., Shanghai RAAS Blood Products Co., Ltd., Omrix Biopharmaceuticals Ltd., Behring GmbH, Option Care Enterprises, Inc., ADMA Biologics, Inc., and BioScrip, Inc.

To get a detailed table of content (ToC), please click – https://www.coherentmarketinsights.com/ongoing-insight/toc/1712

Key players in the market are focused on launching products in worldwide to enhance their market share. For instance, in November 2017, South Korea-based Green Cross announced to launch its immunodeficiency drugs in U.S. market in 2018, as company is working with the U.S. FDA to prepare additional production-related data on its drug IVIG-SN, human normal immunoglobulin G for intravenous administration

Key players in the market are also focused on raising investment to aid their product development strategies. For instance, in January 2018, GigaGen received US$ 3 million grant from the National Institutes of Health to develop novel antibody therapies for patients with immune deficiencies.

Major market players are focused on product development to expand their product portfolio. For instance, in May 2018, Evolve Biologics, a division of Therapure Biopharma Inc., announced the start of phase III clinical trial of PlasmaCap IG (Intravenous Immunoglobulin or “IVIG”). The PlasmaCap IG is an investigational IVIG replacement therapy being studied in both adult and pediatric patients with Primary Immune Deficiency Diseases (PIDD).

To understand Research Methodology, please click https://www.coherentmarketinsights.com/ongoing-insight/immunoglobulin-market-1712

Global Immunoglobulin Market Taxonomy:

By Product:

• IgG
• IgA
• IgM
• IgE
• IgD

By Mode of Delivery:

• Intravenous
• Subcutaneous

By Region:

• North America
• Latin America
• Europe
• Asia Pacific
• Middle East
• Africa

Other Related Reports:

CHRONIC LIVER DISEASES THERAPEUTICS MARKET ANALYSIS

LIVER DISEASES THERAPEUTICS MARKET ANALYSIS

GENERIC DRUGS MARKET ANALYSIS

Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.

To know more about us, please visit our website – www.coherentmarketinsights.com

Contact:

Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837

This content has been distributed via CDN Newswire press release distribution service. For press release enquires please mail us at contact@cdnnewswire.com.